{
}
Pfizer is navigating challenges, including a reinstated lawsuit affecting its diversity fellowship program, which has pressured its share price. As of January 9, 2025, shares closed at EUR 26.03, reflecting a slight decline, while UBS and JPMorgan maintain a "Neutral" rating with price targets of USD 29 and USD 30, respectively. Despite uncertainties, Pfizer reported strong fourth-quarter results, exceeding expectations with revenues of $17.76 billion, and is targeting sales of $61 to $64 billion for 2025.
UBS has increased its price target for JPMorgan from $276 to $287, maintaining a "Buy" rating, following strong fourth-quarter results. Analyst Erika Najarian highlighted the bank's robust business development and alignment with key themes for 2025, including capital market recovery and US economic resilience.
At the J.P. Morgan Healthcare Conference, Pfizer CEO Albert Bourla addressed an impending $17B 'LOE wave' due to patent losses, while highlighting acquisitions expected to generate $20B in annual sales by 2030. Johnson & Johnson announced a $14.6B acquisition of Intra-Cellular Therapies, aiming to enhance its portfolio with the FDA-approved drug Caplyta. Meanwhile, Moderna revealed a significant cut to its 2025 sales guidance, prompting a 20% drop in its stock.
Pfizer's Array BioPharma and Sandoz have settled a patent-infringement lawsuit regarding generic versions of the skin-cancer drug Mektovi. The settlement prevents Sandoz from launching its generic products until the expiration of six asserted patents, with three expiring in October 2033, two in August 2030, and one in July 2031.
The global cancer immunotherapy market is projected to reach $135.2 billion in 2024, growing at a CAGR of 9.8% to $236.9 billion by 2030, driven by rising cancer prevalence and demand for effective treatments. North America leads the market, while Asia-Pacific is the fastest-growing region. Monoclonal antibodies dominate the product segment, with lung cancer applications holding the largest market share, and breast cancer expected to grow the fastest.
U.S. stock indexes closed lower on Tuesday, led by a nearly 2% drop in the Nasdaq, as strong economic data raised inflation concerns and clouded expectations for rate cuts. The Dow fell by over 150 points, while Treasury yields surged, with the 10-year yield reaching its highest since April at 4.691%. Vaccine stocks like Moderna and Pfizer saw gains following the first reported bird flu death in the U.S. this week.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison brings extensive experience in clinical development, having overseen the approval of several notable drugs. He expressed enthusiasm for joining the innovative company and contributing to its mission of developing transformative gene-based medicines.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, including leadership roles at AstraZeneca and Pfizer, Morrison's expertise in clinical development is expected to enhance the company's innovative pipeline. He has overseen the development of notable drugs such as Tagrisso®, Imfinzi®, and Lynparza®.
The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
Roche is projected to lead the pharmaceutical industry in sales by 2025, despite not having any products in the top drug rankings. Eli Lilly and Novo Nordisk are expected to rise in the rankings, with combined sales from their GLP-1 drugs surpassing $70 billion this year. Meanwhile, Pfizer is anticipated to drop from fifth to ninth place, while Merck & Co. and AbbVie are expected to secure the second and third spots, respectively.
Pfizer Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Pfizer faces challenges as share price shows mixed performance in 2025
United States Dollar
Euro
Merck & Co., Inc.
Pfizer Inc.
USA
CHE
Albert Bourla
Chris Schott
Raphael Schicho
Akash Tewari
Show more
16:00 04.02.2025
ubs raises jpmorgan price target to 287 dollars maintaining buy rating
United States Dollar
Barclays PLC
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
JPMorgan Chase & Co.
Pfizer Inc.
CHE
USA
Erika Najarian
Show more
13:37 16.01.2025
jpmorgan conference highlights major acquisitions and strategic plans in healthcare industry
United States Dollar
Intra-Cellular Therapies, Inc.
Johnson & Johnson
Vertex, Inc.
Pfizer Inc.
Moderna, Inc.
USA
Albert Bourla
Joaquin Duato
Reshma Kewalramani
Show more
20:35 13.01.2025
pfizer and sandoz settle patent dispute over mektovi cancer drug copies
18:46 10.01.2025
global cancer immunotherapy market projected to reach 236.9 billion by 2030
United States Dollar
GSK plc
Bristol-Myers Squibb Company
Bayer AG
Eli Lilly and Company
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Immunocore Holdings plc
AstraZeneca PLC
Amgen Inc.
F. Hoffmann-La Roche Ltd.
IND
FRA
ARG
CAN
ESP
USA
BRA
CHN
MEX
DEU
ITA
JPN
GBR
KOR
Show more
10:06 10.01.2025
indexes decline as economic data raises inflation concerns and rate cut fears
22:27 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors
United States Dollar
Pfizer Inc.
AstraZeneca PLC
CRISPR Therapeutics AG
Merck & Co., Inc.
USA
Briggs Morrison
Samarth Kulkarni
Show more
14:04 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors election
United States Dollar
Vertex Pharmaceuticals Inc
AstraZeneca PLC
Bayer AG
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Merck & Co., Inc.
CHE
Briggs Morrison
Samarth Kulkarni
Show more
14:00 07.01.2025
semaglutides market projected to reach 36.87 billion by 2028
United States Dollar
Adocia SA
Sanofi SA
Eli Lilly and Company
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Limited
Boehringer Ingelheim International GmbH
Glaxosmithkline plc
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis International AG
Bristol-Myers Squibb Company
Novo Nordisk A/S
Cipla Limited
Biocon Limited
Teva Pharmaceutical Industries Ltd
AstraZeneca PLC
Amgen Inc.
ITA
IND
FRA
IDN
CAN
ESP
BRA
USA
RUS
CHN
DEU
AUS
JPN
GBR
KOR
Show more
10:12 06.01.2025
roche set to lead global pharma sales in 2025 as rivals rise
United States Dollar
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
ABBVIE
Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca PLC
Gilead Sciences, Inc.
GSK plc
Eli Lilly and Co
Johnson & Johnson
Novo Nordisk A/S
Robert F. Kennedy Jr.
Show more
19:07 03.01.2025
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Cryptocurrency Trends
Government Economic Policies
Private Equity Deals
CEO Changes
Workplace Trends
Central Bank Actions
Central Banks and Digital Currencies
Venture Capital Investments
Retail and Consumer Goods
Fintech Startups
Finance Mergers & Acquisitions
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Tencent Holdings Ltd
Google Inc.
Nikkei 225
Grab2Go AS
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
New Taiwan Dollar
Indonesian Rupiah
Egyptian Pound
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Saudi Riyal
Thai Baht
People: